Form 4: Edgewise Director Exercises Options, Sells Shares

Edgewise Therapeutics Director Badreddin Edris exercised stock options and subsequently sold 115,471 shares of common stock for an average price of $29.44 per share.

Summary

• Badreddin Edris, a Director at Edgewise Therapeutics, Inc. (EWTX), reported transactions on January 21, 2026.
• The transactions involved the exercise of multiple stock options to acquire a total of 115,471 shares of common stock.
• The acquisition prices for these shares ranged from $0.39 to $1.93 per share.
• Immediately following the option exercises, Mr. Edris sold all 115,471 acquired shares of common stock.
• The sales were executed at an average price of $29.44 per share, with individual transaction prices ranging from $29.00 to $29.77.
• These sales were conducted pursuant to a Rule 10b5-1 Plan adopted by Mr. Edris on September 24, 2025.
• Following these reported transactions, Mr. Edris beneficially owns 19,820 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a director's exercise of stock options and subsequent sale of a significant number of shares. While the sale indicates a realization of substantial gains, it also represents a reduction in direct insider ownership. The transaction was conducted under a Rule 10b5-1 plan, suggesting pre-planned personal financial management rather than a reaction to new company-specific news.

Positives

• The director realized substantial gains by exercising stock options at significantly lower prices (ranging from $0.39 to $1.93) and selling the shares at a much higher market price (average of $29.44).
• The high sale price achieved by the director indicates a strong market valuation for Edgewise Therapeutics' common stock at the time of the transaction.

Negatives

• The director sold a significant number of shares (115,471), which represents a substantial reduction in their direct beneficial ownership in the company.
• While executed under a 10b5-1 plan, a large insider sale could be perceived by some investors as a reduction in the director's conviction or a signal for personal diversification.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide direct information on broader industry trends or the competitive landscape for Edgewise Therapeutics.

Comparison to Industry Standards

• As an insider transaction report, this filing does not contain information suitable for direct comparison to global industry benchmarks, specific comparable companies, projects, or results.

Stakeholder Impact

• Shareholders may interpret the director's sale as a positive sign, indicating that the director is realizing value from their holdings at a favorable market price.
• Conversely, some shareholders might view the significant reduction in direct insider ownership as a potential signal, although the Rule 10b5-1 plan mitigates concerns about opportunistic timing.

Next Steps

• The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported range.

Key Dates

Recommendation

The director's sale of a substantial number of shares, while significant, was executed under a pre-arranged Rule 10b5-1 plan, which often indicates personal financial planning rather than a reaction to new material non-public information. The high sale price suggests a strong market valuation for Edgewise Therapeutics at the time of the transaction. However, the reduction in direct insider ownership warrants a 'hold' recommendation, encouraging investors to monitor future company developments and insider sentiment rather than making immediate buy or sell decisions based solely on this transaction.

Keywords

Edgewise Therapeutics, EWTX, Insider Trading, Form 4, Stock Options, Share Sale, Director Transaction, Badreddin Edris, Rule 10b5-1